Skip to content

US · ELOX · BIOTECHNOLOGY

Eloxx Pharmaceuticals, Inc. (ELOX) intrinsic value and stock valuation

$10.69as of 2026-11-21 · Mkt cap 60.38M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Eloxx Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ELOX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ELOX’s statements →

Eloxx Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Watertown, MA 02476 eloxxpharma.com

How the business is doing

Fiscal 2009–2025, USD

Revenue
$0.00
20092025
Net income
-$-6M
20092025
Free cash flow
$0.00
20112025
Total equity
-$-11.91M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2009–2025, USD
20252024202320222021
Revenue$0.00——$0.00$0.00
Operating income-$-6.44M——-$-34.42M-$-42.35M
Net income-$-6M——-$-36.06M-$-66.73M
EPSd-$-5.36M——-$-180.3M-$-417.06M
Operating cash flow-$-6.33M-$-4.71M-$-14.34M-$-31.84M-$-35M
Capital expenditure$6.33M$0.00$0.00-$-70K-$-90K
Free cash flow$0.00-$-4.71M-$-14.34M-$-31.91M-$-35.09M
Total assets$5.27M$2.98M$1.71M$21.1M$45.1M
Total debt$1M$6.52M$3.97M$13.4M$13.5M
Net debt-$-3.79M$6.41M$2.83M-$-6.08M-$-29.11M
Total equity-$-11.91M-$-24.34M-$-22.6M-$-10.66M$22.4M
Cash and short-term investments$4.79M$110K$1.13M$19.5M$42.6M
Income statement
20252022202120202019
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$690K$960K$570K$560K
Gross profit$0.00-$-690K-$-960K-$-570K-$-560K
Research and development expenses$3.06M$23.7M$22.9M$14.6M$25.8M
Selling, general and administrative expenses$3.38M$10M$18.5M$14.3M$24.2M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$6.44M$33.7M$41.4M$28.9M$50M
Cost and expenses$6.44M$34.4M$42.4M$29.4M$50.6M
Interest income$30K$270K$10K$320K$1.37M
Interest expense$1.05M$1.95M$1.26M$1.41M$1.62M
Depreciation and amortization$0.00$690K$960K$570K$560K
Ebitda-$-4.95M-$-33.5M-$-64.51M-$-28.87M-$-50M
Operating income-$-6.44M-$-34.42M-$-42.35M-$-29.44M-$-50.55M
Total other income/expenses, net$440K-$-1.72M-$-24.38M-$-5.14M-$-320K
Income before tax-$-6M-$-36.14M-$-66.73M-$-34.58M-$-50.87M
Income tax expense$0.00-$-80K$0.00$0.00$0.00
Net income-$-6M-$-36.06M-$-66.73M-$-34.58M-$-50.87M
Weighted average shares outstanding$1.12M$200K$160K$90K$90K
Weighted average diluted shares outstanding$1.12M$200K$160K$90K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$4.79M$110K$1.13M$19.5M$42.6M
Net receivables$0.00$2.72M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.27M$2.98M$1.55M$20.1M$43.5M
Property, plant and equipment, net$0.00$0.00$160K$990K$1.66M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$160K$990K$1.66M
Total assets$5.27M$2.98M$1.71M$21.1M$45.1M
Accounts payable$2.71M$5.35M$5.7M$3.02M$1.38M
Short-term debt$1M$6.52M$2.35M$4.69M$660K
Deferred revenue$0.00$13.4M$13M$0.00$0.00
Total current liabilities$17.2M$27.3M$22.7M$23.1M$9.96M
Long-term debt$0.00$0.00$1.61M$8.69M$12.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$1.61M$8.69M$12.8M
Capital lease obligations$0.00$0.00$140K$140K$800K
Total liabilities$17.2M$27.3M$24.3M$31.8M$22.8M
Common stock$50K$40K$30K$20K$870K
Retained earnings-$-300.58M-$-294.58M-$-291.44M-$-274.39M-$-238.32M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-11.91M-$-24.34M-$-22.6M-$-10.66M$22.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1M$6.52M$3.97M$13.4M$13.5M
Net debt-$-3.79M$6.41M$2.83M-$-6.08M-$-29.11M
Cash flow statement
20252024202320222021
Net income-$-6M-$-3.14M-$-17.05M-$-36.06M-$-66.73M
Depreciation and amortization$0.00$160K$810K$690K$960K
Stock-based compensation$230K$540K$1.97M$0.00$0.00
Change in working capital$520K-$-2.36M$840K-$-120K-$-1.03M
Accounts receivable$2.36M-$-2.36M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.63M-$-350K$2.68M$1.64M-$-320K
Net cash provided by operating activities-$-6.33M-$-4.71M-$-14.34M-$-31.84M-$-35M
Investments in property, plant and equipment$0.00$0.00$0.00-$-70K-$-90K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$40K$310K-$-70K$2.06M
Common stock issued$0.00$0.00$4.89M$0.00$47.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11M$3.44M-$-4.08M$8.81M$50.8M
Net change in cash-$-14.68M-$-1.24M-$-18.11M-$-23.1M$17.8M
Cash at end of period$4.79M$120K$1.35M$19.5M$42.6M
Operating cash flow-$-6.33M-$-4.71M-$-14.34M-$-31.84M-$-35M
Capital expenditure$6.33M$0.00$0.00-$-70K-$-90K
Free cash flow$0.00-$-4.71M-$-14.34M-$-31.91M-$-35.09M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Eloxx Pharmaceuticals, Inc.

        Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.

        CEO
        Sumit Aggarwal
        Employees
        10
        Beta
        -9.95

        Explore

        Frequently asked questions

        What is the intrinsic value of Eloxx Pharmaceuticals, Inc. (ELOX)?

        InvestorsCraft does not currently publish an intrinsic value for ELOX. How the IC value is calculated.

        Is ELOX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ELOX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.